A clinical vignette is presented to explore the optimal antithrombotic therapy for a patient with atrial fibrillation and prior stroke undergoing percutaneous coronary intervention with stenting.
Case Report (n=1)
What is the optimal antithrombotic therapy for patients with atrial fibrillation who undergo percutaneous coronary intervention with bare-metal or drug-eluting stents?
This clinical vignette highlights the complex decision-making required to determine optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
man with rate-controlled atrial fibrillation (AF), diabetes mellitus, and prior stroke who is receiving warfarin to prevent recurrent stroke presents to the emergency department with chest pain, elevated serum troponin, and an ECG that demonstrates ST depression in the precordial leads. Cardiac catheterization reveals an ulcerated plaque and partially obstructive thrombus in the left circumflex coronary artery. Percutaneous coronary intervention is performed with placement of 2 baremetal stents. What is the optimal antithrombotic therapy? What is the optimal antithrombotic therapy if the patient receives drug-eluting stents instead of bare-metal stents?
Paikin et al. (Mon,) conducted a case report in Atrial fibrillation and coronary artery stents (n=1). Triple antithrombotic therapy was evaluated. A clinical vignette is presented to explore the optimal antithrombotic therapy for a patient with atrial fibrillation and prior stroke undergoing percutaneous coronary intervention with stenting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: